Inhibition of prostate cancer growth by estramustine and etoposide

Cancer

Volumn 75, Issue 7 S, 1995, Pages 1920-1926

  Pienta, Kenneth J ^a   Redman, Bruce G ^a   Hussain, Maha ^a   Esper, Peggy S ^a   Flaherty, Lawrence E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adenocarcinoma; Dunning; estramustine; etoposide; hormone refractory; prostate cancer

Indexed keywords

ESTRAMUSTINE; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ADULT; ALOPECIA; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DNA REPLICATION; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0028963455     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950401)75:7+<1920::AID-CNCR2820751627>3.0.CO;2-Y     Document Type: Article

References (37)

1. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
2. Cancer as a disease of DNA organization and dynamic cell structure
3. Cell structure and DNA organization
4. The role of the nuclear matrix in the organization and function of DNA
5. Identification of nuclear matrix proteins in the cancer and normal rat prostate
6. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostatic cancer
7. A common set of nuclear matrix proteins in prostate cancer
8. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM‐26 and m‐AMSA
9. Inhibition of primer RNA formation in CCRF‐CEM leukemia cells by fludarabine tri‐phosphate
10. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix
11. Effects of antileukemia agents on nuclear matrix‐bound DNA replication in CCRF‐CEM leukemia cells
12. Etoposide in prostatic cancer: experimental studies and phase II trials in patients with bidimensionally measurable disease
13. Oral etoposide in the treatment of hormone‐refractory prostate cancer
14. Phase II study of etoposide for carcinoma of the prostate
15. Phase II study of estramustine and vinblasline, two microtubule inhibitors, in hormone‐refractory prostate cancer
16. Comparison of flutamide and EMCYT in hormone‐refractory metastatic prostate cancer
17. Use of estramustine phosphate in prostate cancer by the national prostatic cancer project and by Roswell Park Memorial Institute
18. Hormone‐independent, non‐alkylating mechanism of cytotoxicity for estramustine
19. Nuclear protein matrix as a target for estramustine‐induced cell death
20. Proteolytic cleavage of high molecular weight microtubule associated proteins by the prostatic estramustine binding protein
21. A combination of oral estramustine and oral etoposide for the treatment of hormone refractory prostate cancer
22. A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome
23. Supercoiled loops and eukaryotic DNA replication
24. Newly replicated DNA is associated with DNA topoiosomerase II in cultures rat prostatic adenocarcinoma cells
25. Localization of topoisomerase II in mitotic chromosomes
26. Multienzyme complex for metabolic channeling in mammalian DNA replication
27. Reduced topoisomerase II‐mediated DNA cleavage in VP‐16 resistant human leukemic cell line
28. The clinical pharmacology of etoposide
29. Experiences with estrmustine phosphate in prostate cancer
30. Cytotoxic chemotherapy for advance hormone resistant prostate cancer
31. Chemotherapy for prostate carcinoma
32. Comparison of the effects of high dose estramustin phosphate and mitomycin c on the time to progression an length of survival of patients with progressive, advanced endocrine‐independent prostatic cancer: an interim analysis c EORTC‐GU group study no. 30865
33. Suramin: a novel growth factor antagonist with activity in hormone‐refractory prostate cancer
34. Prostat specific antigen as a marker for prostatic cancer: a monoclonal and polyclonal immunoassay compared
35. Estramustine and vinblastine: use of PSA as a clinical trial end‐point for hormone refractory prostate cancer
36. Prostate‐specific antigen as a measure of disease outcome in metastatic hormone‐refractory prostate cancer